Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was to evaluate efficacy and safety of the new acute treatment of deep venous thrombosis by use of low-molecular-weight heparin compared with standard treatment using unfractionated heparin, especially concerning long-term morbidity.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aalborg Universitetshospital; Aalborg University Hospital
• Collaborator: Aalborg University
• Treatments: Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• First DVT with or without known risk factors except overt cancer

• Second DVT more than two years after the first if the patient was without clinical signs of CVI.

Exclusion Criteria:

• Contraindication to anticoagulation therapy

• Candidate to thrombectomy with arterious-venous fistula or thrombolytic therapy

• Known cancer at the time of the DVT diagnosis

• Patients unable to cooperate for anticoagulation therapy or manage the tests.